p53 tetramerization: at the center of the dominant-negative effect of mutant p53
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor functions as a tetrameric transcription factor to regulate hundreds of genes—many in a tissue-specific manner. Missense mutations in cancers in the p53 DNA-binding and tetramerization domains cement the importance of these domains in tumor suppression. p53 mutants with a functional tetramerization domain form mixed tetramers, which in some cases have dominant-negative effects (DNE) that inactivate wild-type p53. DNA damage appears necessary but not sufficient for DNE, indicating that upstream signals impact DNE. Posttranslational modifications and protein–protein interactions alter p53 tetramerization affecting transcription, stability, and localization. These regulatory components limit the dominant-negative effects of mutant p53 on wild-type p53 activity. A deeper understanding of the molecular basis for DNE may drive development of drugs that release WT p53 and allow tumor suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“For example, the main negative regulator of p53, MDM2, ubiquitinates p53 and targets it for proteasomal degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“For example, the main negative regulator of p53, MDM2, ubiquitinates p53 and targets it for proteasomal degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“How p53 makes this decision depends on many factors that are not fully understood (Vousden and Prives 2009).”
BackgroundAnnouncing the worldwide Protein Data Bank
Berman, H., Henrick, K., & Nakamura, H. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb1203-980 · Cited by 3,093
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · cited 1×
“The DNA-binding domain (DBD) of p53 recognizes two sequential decameric motifs (or two half-sites) of DNA, each comprised of 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ (Pu and Py stand for purine and pyrimidine, respectively), separated by up to 13 bp (el-Deiry et al. 1992).”
BackgroundThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · cited 2×
“After DNA damage or stress (such as inflammation, oncogene activation, nutrient deprivation, hypoxia (Harris and Levine 2005), p53 tetramers are observed in the nucleus suggesting that this feature is essential for its transcriptional activity (Gaglia et al. 2013).”
BackgroundOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“For example, the main negative regulator of p53, MDM2, ubiquitinates p53 and targets it for proteasomal degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundTranscriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“p53 initiates several cellular programs such as apoptosis, cell cycle arrest, and senescence (Martinez et al. 1991; Yonish-Rouach et al. 1991; Brown et al. 1997; Riley et al. 2008).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“…in this region account for∼20%of germlinemutations inLi-Fraumeni syndrome (LFS), a cancer-predisposition disorder characterized by the presence of a germline p53 mutation (Malkin et al. 1990; Petitjean et al. 2007; Bouaoun et al. 2016), and ∼2% of somatic p53 mutations (Bouaoun et al. 2016).”
BackgroundHow does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 2×
“p53 and p53 mice have survival curves that are intermediate between WT and p53-null (Lang et al. 2004; Olive et al. 2004).”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 5×
“After ionizing radiation (IR), p53R172H/+ embryos show an apoptotic response in the embryonic hypothalamus that is similar to p53-null embryos providing clear evidence for inactivation of WT p53; that is, a DNE (Lang et al. 2004).”
BackgroundInfluentialSelf-citationRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“As there is precedent for small molecules to restore WT p53 conformation of p53 DBD mutants (Bykov et al. 2002), the design of small molecules that aim at recovering tetrameric structures of the protein could serve as therapeutic approaches for p53 TDmutant cancers (Gordo et al. 2008).”
BackgroundShieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760 · cited 1×
“In support of this concept, Bougeard et al. (2015) report earlier tumor onset in a French cohort of LFS carriers of tetramerization-intact p53 mutants (e.g., DBD mutants; 21.3 yr) as compared with carriers of tetramerization-deficient mutants (p53 TD or truncation mutants; 28.5 yr).”
BackgroundInfluentialAcetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752 · cited 1×
“The evidence presented above places the TD as an essential domain for regulating p53 tumor suppressive activities, in addition to reports that show the DBD fine-tunes cell fate decisions between cell cycle and apoptotic responses (Sykes et al. 2006; Tang et al. 2006).”
BackgroundStommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738 · cited 2×
“p53 TD peptides are able to block hyperactive export of p53 in neuroblastoma cells and lead to increased p53 nuclear localization (Stommel et al. 1999).”
BackgroundBouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579 · cited 2×
“Many assays take advantage of overexpression systems to examine a role for mutant p53 in inhibiting WT p53 activity (Lavigueur et al. 1989; Farmer et al. 1992; Kern et al. 1992; Harvey et al. 1995; Hegi et al. 2000; Klein et al. 2000; Chan et al. 2004; Xu et al. 2011; Aubrey et al. 2018;Walerych et…”
BackgroundMutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556 · cited 3×
“The p53 R335H mutation has been found in cancer and reported as functional in different studies (Imagawa et al. 2009; Giacomelli et al. 2018).”
BackgroundGain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441 · cited 3×
“Boettcher et al. (2019) recently reported a role for mutant p53 DNE in myeloid malignancies.”
BackgroundInfluentialHow p53 binds DNA as a tetramer
McLure, K. G., & Lee, P. W. K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3342 · Cited by 260
Yakovlev, V. A., Bayden, A. S., Graves, P. R., Kellogg, G. E., & Mikkelsen, R. B. (2010) · Biochemistry · doi:10.1021/bi100564w · Cited by 56 · cited 1×
“A nitric oxide-dependent p53 response occurs on p53Y327 by nitration and stabilizes the p53 tetramer, thus increasing transcriptional activity (Yakovlev et al. 2010).”
Background
Cited by
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Metadata
- Authors
- Gencel-Augusto, J., & Lozano, G.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2020-09-01
- Volume
- 34
- Issue
- 17-18
- Pages
- 1128-1146
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W3081842013
- Cited by
- 124
- References
- 26
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.